LEGN Presents LB2102 Phase 1 Data: 28.6% ORR, 78.6% DCR in Solid Tumors, CARVYKTI Shows Durable Efficacy in Multiple Myeloma
Legend Biotech Corporation American Depositary Shares · Now $27.16
-0.7% in 1h after detection
Post-detection moves
1h
-0.7%
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS